Clinical Trial Update: Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study of Tariquidar (XR9576), a selective MDR-1 inhibitor, for chemotherapy-resistant advanced breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tariquidar (tariquidar)

Snippet

Sponsor: QLT Inc. | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED